N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1DR activation.
Sign Up to like & getrecommendations! Published in 2019 at "Toxicology and applied pharmacology"
DOI: 10.1016/j.taap.2019.114789
Abstract: Previous studies showed that dopamine (DA) significantly reduces the frequency of cancer stem-like cells (CSC) and enhances the efficacy of sunitinib (SUN) in the treatment of breast cancer and non-small cell lung cancer (NSCLC). To… read more here.
Keywords: containing compound; arylpiperazine containing; pancreatic cancer; cancer ... See more keywords